Avedro Announces FDA Priority Review Status for Corneal Cross-linking New Drug Application

Avedro Announces FDA Priority Review Status for Corneal Cross-linking New Drug Application

November 25, 2013

If Approved, Avedro Could Be Entitled to Seven Years Market Exclusivity

WALTHAM, Mass.--(BUSINESS WIRE)--Avedro Inc, a Boston-based ophthalmic medical device and pharmaceutical company announces that it received notification from the U.S. Food and Drug Administration (FDA) stating that their NDA for riboflavin ophthalmic solution/KXL system has been filed, and has been granted priority review status. The priority review status places the application action date (PDUFA) at March 15th, 2014.

Syros Pharmaceuticals Appoints Stéphane Bancel to Board of Directors

Syros Pharmaceuticals Appoints Stéphane Bancel to Board of Directors

November 21, 2013

WATERTOWN, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals, a life sciences company harnessing breakthroughs in gene control to revolutionize the treatment of cancer and other diseases, announced today that Stéphane Bancel, President and Founding Chief Executive Officer (CEO) of Moderna Therapeutics, and Senior Partner at Flagship Ventures, has joined its Board of Directors.

Flagship VentureLabs™ Introduces Seres Health - Early Leader in the Development of Novel Therapeutics to Treat Diseases of the Human Microbiome

Flagship VentureLabs™ Introduces Seres Health - Early Leader in the Development of Novel Therapeutics to Treat Diseases of the Human Microbiome

November 21, 2013

Company Appoints Dr. Roger J. Pomerantz as Chairman

Flagship Takes a Stab at Microbiome Therapy With Seres Health

Flagship Takes a Stab at Microbiome Therapy With Seres Health

November 21, 2013

By Luke Timmerman of Xconomy

We live every day with trillions of bacterial neighbors that do all sorts of mysterious things in our guts, good and bad. The broadening scientific understanding of the “microbiome”, powered by the modern tools of genomic analysis, has been in the news for a while.

Moderna Vacuums Up Another $110M to Make Messenger RNA Drugs

Moderna Vacuums Up Another $110M to Make Messenger RNA Drugs

November 20, 2013

By Luke Timmerman of Xconomy

Moderna Therapeutics doesn’t need cash to keep the doors open, like many biotech startups. It just went out and raised a ton of dough, anyway.

The Cambridge, MA-based biotech startup, which is attempting to make injectable messenger RNA molecules that trigger production of protein drugs in the body, has raised a whopping $110 million in new equity financing.

Moderna Therapeutics Announces New Equity Financing, Raising $110M to Develop messenger RNA Therapeutics™

Moderna Therapeutics Announces New Equity Financing, Raising $110M to Develop messenger RNA Therapeutics™

November 20, 2013

Latest round boosts capital reserves to advance numerous drug candidates into clinical testing directly and through strategic partners

Independent Multicenter Trial Demonstrates Utility of BGM Galectin-3(R) Test for Accurately Classifying Risk of Unplanned Hospital Readmissions and Adverse Outcomes in Patients With Heart Failure

Independent Multicenter Trial Demonstrates Utility of BGM Galectin-3(R) Test for Accurately Classifying Risk of Unplanned Hospital Readmissions and Adverse Outcomes in Patients With Heart Failure

November 19, 2013

WALTHAM, Mass., Nov 19, 2013 (GLOBE NEWSWIRE via COMTEX) -- BG Medicine, Inc. announced today the publication of results of an independent multicenter clinical research trial in Europe that enrolled 419 heart failure patients and demonstrated that elevated levels of galectin-3 in blood, as measured using the BGM Galectin-3 Test, were significantly predictive of unplanned hospital readmissions and fatal events during the 12 month follow-up period of the trial. [1]

Tetraphase Reports Third-Quarter 2013 Financial Results

Tetraphase Reports Third-Quarter 2013 Financial Results

November 14, 2013

WATERTOWN, Mass.--(BUSINESS WIRE)-- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today reported financial results for the quarter ended September 30, 2013.

BG Medicine, Inc. Appoints Stephen P. Hall as Chief Financial Officer

BG Medicine, Inc. Appoints Stephen P. Hall as Chief Financial Officer

November 14, 2013

WALTHAM, Mass., Nov. 14, 2013 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), the developer of the BGM Galectin-3® Test, announced today that its Board of Directors has appointed Stephen P. Hall, as the company's Executive Vice President, Chief Financial Officer.

Avedro and the University of Rostock (Germany) Announce Exclusive Intellectual Property Agreement

Avedro and the University of Rostock (Germany) Announce Exclusive Intellectual Property Agreement

November 14, 2013

Avedro will Commercialize Patented Corneal Biomechanical Diagnostic

WALTHAM, Mass.--(BUSINESS WIRE)-- Avedro Inc., a Boston-based ophthalmic medical device and pharmaceutical company, announces today that it has obtained an exclusive license to commercialize scientific patents created at the University of Rostock (Germany). The devices, which will in part be based on these patents, will allow Avedro to bring to market the first ever diagnostic device to accurately assess corneal biomechanical strength.